R. Kristeleit

A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

Iain A. McNeish, JA Ledermann, Lee Webber et al. · Annals of Oncology · 2014 · 82 citations · Full text

Gastrointestinal Oncology, Medicine, Metronomic Therapy +10

Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial

Éric Pujade-Lauraine, Keiichi Fujiwara, JA Ledermann et al. · Gynecologic Oncology · 2019 · 61 citations

Biomarker Analysis, Medicine, Gynecology +8

Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)

R. Kristeleit, Ronnie Shapira‐Frommer, Ana Oaknin et al. · Annals of Oncology · 2016 · 24 citations · Full text

Inhibitor Rucaparib, Brca Mutation, Medicine +7

2700 Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis

R. Kristeleit, Elizabeth M. Swisher, Amit M. Oza et al. · European Journal of Cancer · 2015 · 23 citations

Part 1, Oncology, Medicine +7

2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation

Ronnie Shapira‐Frommer, Amit M. Oza, Susan M. Domchek et al. · European Journal of Cancer · 2015 · 20 citations

Single-agent Rucaparib, Medicine, Metronomic Therapy +8